BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 37,000 Shares of Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 37,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $99.20, for a total value of $3,670,400.00. Following the completion of the transaction, the chief executive officer directly owned 744,709 shares in the company, valued at approximately $73,875,132.80. This represents a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total value of $3,520,080.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total transaction of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Price Performance

BNTX stock opened at $98.13 on Thursday. BioNTech SE Sponsored ADR has a one year low of $79.52 and a one year high of $124.00. The company’s fifty day moving average price is $97.02 and its 200-day moving average price is $95.46. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The company has a market capitalization of $24.82 billion, a PE ratio of -12.53 and a beta of 1.29.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The company had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.BioNTech’s revenue was down 59.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.60) EPS. On average, equities analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 EPS for the current fiscal year.

BioNTech News Summary

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Analyst views remain broadly favorable despite some disagreement. BioNTech has a consensus “Moderate Buy” rating and an average price target of $126, above recent trading levels, with several firms maintaining Buy ratings. Analysts Have Conflicting Sentiments on These Healthcare Companies
• Neutral Sentiment: CEO Ugur Sahin’s recent transactions were made under pre-arranged trading plans rather than in response to newly disclosed business developments. Institutional ownership also remains present, with several large investors increasing their positions, though institutional investors hold only about 15.5% of the stock. BioNTech SEC Form 4 Filing
• Negative Sentiment: BMO Capital Markets downgraded BioNTech from “outperform” to “market perform” and cut its price target from $128 to $105. The reduced target narrows the perceived upside and is the clearest immediate explanation for the stock’s decline. BioNTech Shares Fall After BMO Downgrade and Price Target Cut
• Negative Sentiment: Sahin sold a combined 149,500 shares from September 3 through September 9 for approximately $15.1 million, reducing his holdings in successive transactions. Although the trades were planned in advance, repeated CEO selling can create an overhang and reinforce cautious investor sentiment. BioNTech CEO Insider Selling

Institutional Trading of BioNTech

Large investors have recently made changes to their positions in the business. Larson Financial Group LLC increased its stake in BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after acquiring an additional 127 shares during the last quarter. EFG International AG purchased a new position in shares of BioNTech in the 4th quarter worth approximately $29,000. Caitong International Asset Management Co. Ltd increased its position in shares of BioNTech by 520.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after purchasing an additional 260 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in BioNTech in the second quarter worth $39,000. Finally, Tower Research Capital LLC TRC boosted its stake in BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after buying an additional 305 shares during the period. 15.52% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Canaccord Genuity Group cut their price objective on BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a research report on Monday, August 31st. UBS Group upgraded BioNTech from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $117.00 to $135.00 in a research report on Wednesday, May 27th. Wall Street Zen lowered BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Monday, July 6th. Finally, Citigroup reduced their price objective on BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and an average target price of $126.00.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.